KIT and myelodysplastic syndrome: Only in a clinical trial in patients with AML and MDS targeting CD117 with MGTA-117 a novel antibody drug conjugate with amanitin, an RNA polymerase II inhibitor, unacceptable toxicity was observed and this was most likely due to the amanitin moiety (NCT05223699).